Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-2,621
Closed -$258K 797
2025
Q2
$258K Buy
2,621
+311
+13% +$29.4K ﹤0.01% 728
2025
Q1
$214K Buy
+2,310
New +$213K ﹤0.01% 758
2024
Q4
Sell
-52,129
Closed -$5.03M 817
2024
Q3
$5.03M Sell
52,129
-77,367
-60% -$7.55M 0.04% 325
2024
Q2
$11.9M Sell
129,496
-7,863
-6% -$730K 0.11% 179
2024
Q1
$12.7M Buy
137,359
+807
+0.6% +$75.6K 0.11% 179
2023
Q4
$13M Sell
136,552
-2,476
-2% -$231K 0.12% 172
2023
Q3
$13M Sell
139,028
-1,413
-1% -$131K 0.12% 165
2023
Q2
$12.8M Buy
140,441
+3,087
+2% +$253K 0.13% 181
2023
Q1
$10.1M Buy
+137,354
New +$11.9M 0.09% 217
2022
Q1
Sell
-1,726
Closed -$279K 704
2021
Q4
$279K Sell
1,726
-62,694
-97% -$10.1M ﹤0.01% 601
2021
Q3
$9.61M Sell
64,420
-2,823
-4% -$587K 0.15% 191
2021
Q2
$16.5M Sell
67,243
-2,397
-3% -$629K 0.25% 131
2021
Q1
$18.4M Sell
69,640
-32,690
-32% -$9.22M 0.3% 106
2020
Q4
$30M Sell
102,330
-4,350
-4% -$1.12M 0.54% 46
2020
Q3
$25.2M Buy
106,680
+16,037
+18% +$3.65M 0.53% 50
2020
Q2
$18M Sell
90,643
-15,477
-15% -$2.89M 0.44% 68
2020
Q1
$19.5M Buy
106,120
+3,234
+3% +$575K 0.57% 46
2019
Q4
$17.2M Buy
102,886
+32,775
+47% +$4.87M 0.37% 64
2019
Q3
$9.19M Buy
70,111
+2,901
+4% +$378K 0.2% 127
2019
Q2
$8.16M Sell
67,210
-54,933
-45% -$6.52M 0.18% 137
2019
Q1
$15.1M Sell
122,143
-17,822
-13% -$2.24M 0.34% 64
2018
Q4
$16.4M Buy
139,965
+23,680
+20% +$2.79M 0.39% 59
2018
Q3
$14.5M Sell
116,285
-10,611
-8% -$1.17M 0.32% 63
2018
Q2
$10.8M Sell
126,896
-1,233
-1% -$90.5K 0.25% 90
2018
Q1
$7.73M Buy
128,129
+35,611
+38% +$2.03M 0.18% 123
2017
Q4
$4.88M Buy
92,518
+13,534
+17% +$713K 0.11% 168
2017
Q3
$4.42M Buy
78,984
+4,190
+6% +$222K 0.1% 171
2017
Q2
$4.7M Buy
74,794
+12,453
+20% +$725K 0.12% 161
2017
Q1
$3.19M Buy
+62,341
New +$2.97M 0.08% 206

Other funds holding AMED

Great Lakes Advisors's AMED Position: Q3 2025 in Review

Great Lakes Advisors sold out of Amedisys (AMED) in Q3 2025, closing a stake of 2,621 shares — an estimated $258K sold.

Great Lakes Advisors first reported a position in AMED in Q1 2017 and held it in 29 quarters. The position peaked at $30M in Q4 2020. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Great Lakes Advisors reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Great Lakes Advisors sold 2,621 Amedisys shares in Q3 2025, an estimated $258K.
  • Great Lakes Advisors first reported a position in Amedisys in Q1 2017 and held it in 29 quarters.
  • Great Lakes Advisors's Amedisys position peaked at $30M in Q4 2020.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Great Lakes Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.